@article{MTMT:33636072, title = {S100b in acute ischemic stroke clots is a biomarker for post-thrombectomy intracranial hemorrhages.}, url = {https://m2.mtmt.hu/api/publication/33636072}, author = {Rossi, Rosanna and Douglas, Andrew and Gil, Sara Molina and Jabrah, Duaa and Pandit, Abhay and Gilvarry, Michael and McCarthy, Ray and Prendergast, James and Jood, Katarina and Redfors, Petra and Nordanstig, Annika and Ceder, Erik and Dunker, Dennis and Carlqvist, Jeanette and Szikora, István and Thornton, John and Tsivgoulis, Georgios and Psychogios, Klearchos and Tatlisumak, Turgut and Rentzos, Alexandros and Doyle, Karen M}, doi = {10.3389/fneur.2022.1067215}, journal-iso = {FRONT NEUR}, journal = {FRONTIERS IN NEUROLOGY}, volume = {13}, unique-id = {33636072}, issn = {1664-2295}, abstract = {Post-thrombectomy intracranial hemorrhages (PTIH) are dangerous complications of acute ischemic stroke (AIS) following mechanical thrombectomy. We aimed to investigate if S100b levels in AIS clots removed by mechanical thrombectomy correlated to increased risk of PTIH.We analyzed 122 thrombi from 80 AIS patients in the RESTORE Registry of AIS clots, selecting an equal number of patients having been pre-treated or not with rtPA (40 each group). Within each subgroup, 20 patients had developed PTIH and 20 patients showed no signs of hemorrhage. Gross photos of each clot were taken and extracted clot area (ECA) was measured using ImageJ. Immunohistochemistry for S100b was performed and Orbit Image Analysis was used for quantification. Immunofluorescence was performed to investigate co-localization between S100b and T-lymphocytes, neutrophils and macrophages. Chi-square or Kruskal-Wallis test were used for statistical analysis.PTIH was associated with higher S100b levels in clots (0.33 [0.08-0.85] vs. 0.07 [0.02-0.27] mm2, H1 = 6.021, P = 0.014*), but S100b levels were not significantly affected by acute thrombolytic treatment (P = 0.386). PTIH was also associated with patients having higher NIHSS at admission (20.0 [17.0-23.0] vs. 14.0 [10.5-19.0], H1 = 8.006, P = 0.005) and higher number of passes during thrombectomy (2 [1-4] vs. 1 [1-2.5], H1 = 5.995, P = 0.014*). S100b co-localized with neutrophils, macrophages and with T-lymphocytes in the clots.Higher S100b expression in AIS clots, higher NIHSS at admission and higher number of passes during thrombectomy are all associated with PTIH. Further investigation of S100b expression in AIS clots by neutrophils, macrophages and T-lymphocytes could provide insight into the role of S100b in thromboinflammation.}, keywords = {Thrombus; S100B; Acute ischemic stroke; stroke biomarkers; post-thrombectomy intracranial hemorrhages}, year = {2023}, eissn = {1664-2295}, orcid-numbers = {Szikora, István/0000-0003-3730-3278} } @article{MTMT:33623134, title = {Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System. The PICTURE Randomized Clinical Trial.}, url = {https://m2.mtmt.hu/api/publication/33623134}, author = {Loevner, Laurie A and Kolumban, Balint and Hutóczki, Gábor and Dziadziuszko, Katarzyna and Bereczki, Dániel and Bagó, Attila György and Pichiecchio, Anna}, doi = {10.1097/RLI.0000000000000944}, journal-iso = {INVEST RADIOL}, journal = {INVESTIGATIVE RADIOLOGY}, volume = {58}, unique-id = {33623134}, issn = {0020-9996}, abstract = {Developing new high relaxivity gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) allowing dose reduction while maintaining similar diagnostic efficacy is needed, especially in the context of gadolinium retention in tissues. This study aimed to demonstrate that contrast-enhanced MRI of the central nervous system (CNS) with gadopiclenol at 0.05 mmol/kg is not inferior to gadobutrol at 0.1 mmol/kg, and superior to unenhanced MRI.PICTURE is an international, randomized, double-blinded, controlled, cross-over, phase III study, conducted between June 2019 and September 2020. Adult patients with CNS lesions were randomized to undergo 2 MRIs (interval, 2-14 days) with gadopiclenol (0.05 mmol/kg) then gadobutrol (0.1 mmol/kg) or vice versa. The primary criterion was lesion visualization based on 3 parameters (border delineation, internal morphology, and contrast enhancement), assessed by 3 off-site blinded readers. Key secondary outcomes included lesion-to-background ratio, enhancement percentage, contrast-to-noise ratio, overall diagnostic preference, and adverse events.Of the 256 randomized patients, 250 received at least 1 GBCA administration (mean [SD] age, 57.2 [13.8] years; 53.6% women). The statistical noninferiority of gadopiclenol (0.05 mmol/kg) to gadobutrol (0.1 mmol/kg) was achieved for all parameters and all readers (n = 236, lower limit 95% confidence interval of the difference ≥-0.06, above the noninferiority margin [-0.35], P < 0.0001), as well as its statistical superiority over unenhanced images (n = 239, lower limit 95% confidence interval of the difference ≥1.29, P < 0.0001).Enhancement percentage and lesion-to-background ratio were higher with gadopiclenol for all readers (P < 0.0001), and contrast-to-noise ratio was higher for 2 readers (P = 0.02 and P < 0.0001). Three blinded readers preferred images with gadopiclenol for 44.8%, 54.4%, and 57.3% of evaluations, reported no preference for 40.7%, 21.6%, and 23.2%, and preferred images with gadobutrol for 14.5%, 24.1%, and 19.5% (P < 0.001).Adverse events reported after MRI were similar for gadopiclenol (14.6% of patients) and gadobutrol (17.6%). Adverse events considered related to gadopiclenol (4.9%) and gadobutrol (6.9%) were mainly injection site reactions, and none was serious.Gadopiclenol at 0.05 mmol/kg is not inferior to gadobutrol at 0.1 mmol/kg for MRI of the CNS, confirming that gadopiclenol can be used at half the gadolinium dose used for other GBCAs to achieve similar clinical efficacy.}, year = {2023}, eissn = {1536-0210}, pages = {307-313}, orcid-numbers = {Bereczki, Dániel/0000-0002-8374-0500} } @article{MTMT:33364842, title = {Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases}, url = {https://m2.mtmt.hu/api/publication/33364842}, author = {Woldmar, N and Schwendenwein, A and Kuras, M and Szeitz, Beáta and Boettiger, K and Sólyom-Tisza, Anna and Laszlo, Viktoria and Reiniger, Lilla and Bagó, Attila György and Szállási, Zoltán and Moldvay, Judit and Szász, Attila Marcell and Malm, J and Horvatovich, P and Pizzatti, L and Domont, G B and Rényi-Vámos, Ferenc István and Hoetzenecker, K and Hoda, M A and Marko-Varga, G and Schelch, K and Megyesfalvi, Zsolt and Rezeli, M and Döme, Balázs}, doi = {10.1016/j.esmoop.2022.100741}, journal-iso = {ESMO OPEN}, journal = {ESMO OPEN}, volume = {8}, unique-id = {33364842}, issn = {2059-7029}, abstract = {Background Brain metastases are associated with considerable negative effects on patients’ outcome in lung adenocarcinoma (LADC). Here, we investigated the proteomic landscape of primary LADCs and their corresponding brain metastases. Materials and methods Proteomic profiling was conducted on 20 surgically resected primary and brain metastatic LADC samples via label-free shotgun proteomics. After sample processing, peptides were analyzed using an Ultimate 3000 pump coupled to a QExactive HF-X mass spectrometer. Raw data were searched using PD 2.4. Further data analyses were carried out using Perseus, RStudio and GraphPad Prism. Proteomic data were correlated with clinical and histopathological parameters and the timing of brain metastases. Mass spectrometry-based proteomic data are available via ProteomeXchange with identifier PXD027259. Results Out of the 6821 proteins identified and quantified, 1496 proteins were differentially expressed between primary LADCs and corresponding brain metastases. Pathways associated with the immune system, cell-cell/matrix interactions and migration were predominantly activated in the primary tumors, whereas pathways related to metabolism, translation or vesicle formation were overrepresented in the metastatic tumors. When comparing fast- versus slow-progressing patients, we found 454 and 298 differentially expressed proteins in the primary tumors and brain metastases, respectively. Metabolic reprogramming and ribosomal activity were prominently up-regulated in the fast-progressing patients (versus slow-progressing individuals), whereas expression of cell-cell interaction- and immune system-related pathways was reduced in these patients and in those with multiple brain metastases. Conclusions This is the first comprehensive proteomic analysis of paired primary tumors and brain metastases of LADC patients. Our data suggest a malfunction of cellular attachment and an increase in ribosomal activity in LADC tissue, promoting brain metastasis. The current study provides insights into the biology of LADC brain metastases and, moreover, might contribute to the development of personalized follow-up strategies in LADC.}, keywords = {brain metastasis; lung adenocarcinoma; CLINICAL PROTEOMICS; Intertumoral heterogeneity}, year = {2023}, eissn = {2059-7029}, orcid-numbers = {Szeitz, Beáta/0000-0001-6414-0537; Sólyom-Tisza, Anna/0000-0001-5871-2930; Reiniger, Lilla/0000-0003-2248-4264; Szállási, Zoltán/0000-0001-5395-7509; Szász, Attila Marcell/0000-0003-2739-4196; Rényi-Vámos, Ferenc István/0000-0002-0555-2096; Megyesfalvi, Zsolt/0000-0001-8552-6500; Döme, Balázs/0000-0001-8799-8624} } @article{MTMT:32925428, title = {Aneurysm treatment with the Woven EndoBridge (WEB) device in the combined population of two prospective, multicenter series : 5-year follow-up}, url = {https://m2.mtmt.hu/api/publication/32925428}, author = {Pierot, Laurent and Szikora, István and Barreau, Xavier and Holtmannspoetter, Markus and Spelle, Laurent and Klisch, Joachim and Herbreteau, Denis and Costalat, Vincent and Fiehler, Jens and Januel, Anne-Christine and Liebig, Thomas and Stockx, Luc and Weber, Werner and Berkefeld, Joachim and Moret, Jacques and Molyneux, Andy and Byrne, James}, doi = {10.1136/neurintsurg-2021-018414}, journal-iso = {J NEUROINTERV SURG}, journal = {JOURNAL OF NEUROINTERVENTIONAL SURGERY}, volume = {15}, unique-id = {32925428}, issn = {1759-8478}, abstract = {Evaluating a new endovascular treatment for intracranial aneurysms must not only demonstrate short-term safety and efficacy, but also evaluate longer-term outcomes (eg, delayed complications, anatomical results, retreatment). The current analysis reports the 5-year clinical and anatomical results of Woven EndoBridge (WEB) treatment in two European combined trial populations (WEBCAST (WEB Clinical Assessment of Intrasaccular Aneurysm Therapy) and WEBCAST-2).All adverse events occurring between the procedure and 5-year follow-up were independently evaluated by an expert. Aneurysm occlusion was evaluated by an independent core laboratory using a three-grade scale: complete occlusion, neck remnant, and aneurysm remnant. In cases where data were not available at 5-year follow-up, the last observation carry forward (LOCF) method was used.The safety and efficacy populations comprised 100 patients and 95 aneurysms, respectively. No adverse event related to the device occurred after the procedure during the 5-year follow-up period. Mortality at 5 years was 7.0% (7/100 patients) including mortality related to the WEB (0/100, 0.0%), the procedure (1/100, 1.0%), and another condition (6/100, 6.0%). At 5 years, complete aneurysm occlusion was observed in 49/95 (51.6%) aneurysms, neck remnant in 25/95 (26.3%), and aneurysm remnant in 21/95 (22.1%). Retreatment rate at 5 years was 11.6% (11/95 aneurysms).This analysis conducted in a population of patients with wide-neck bifurcation aneurysms confirms WEB's safety profile. Additional evidence demonstrates good stability of aneurysm occlusion with adequate occlusion (complete occlusion or neck remnant) at 5 years in 77.9% of aneurysms with a low retreatment rate (11.6%).WEBCAST and WEBCAST-2: Unique identifier: NCT01778322.}, keywords = {Aneurysm}, year = {2023}, eissn = {1759-8486}, pages = {552-557}, orcid-numbers = {Szikora, István/0000-0003-3730-3278} } @article{MTMT:32720760, title = {Real‐world user experience with seizure detection wearable devices in the home environment}, url = {https://m2.mtmt.hu/api/publication/32720760}, author = {Hadady, Levente and Klivényi, Péter and Fabó, Dániel and Beniczky, Sándor}, doi = {10.1111/epi.17189}, journal-iso = {EPILEPSIA}, journal = {EPILEPSIA}, volume = {64}, unique-id = {32720760}, issn = {0013-9580}, year = {2023}, eissn = {1528-1167}, pages = {S72-S77}, orcid-numbers = {Hadady, Levente/0000-0002-3716-3335; Klivényi, Péter/0000-0002-5389-3266; Fabó, Dániel/0000-0001-5141-5351} } @article{MTMT:33556642, title = {Központi idegrendszeri vasculitis gyanújával vizsgált betegek vizsgálati eredményeinek retrospektív feldolgozása (OKITI, 2016–2021)}, url = {https://m2.mtmt.hu/api/publication/33556642}, author = {Szirmai, Danuta and Futó, Claudia and Frendl, Anita and Kis, Balázs and Kondor, Máté and Pozsár, Kinga and Kamondi, Anita}, journal-iso = {IDEGGYÓGY SZEMLE PROC}, journal = {IDEGGYÓGYÁSZATI SZEMLE PROCEEDINGS / CLINICAL NEUROSCIENCE PROCEEDINGS}, volume = {7}, unique-id = {33556642}, issn = {2498-6240}, year = {2022}, pages = {186}, orcid-numbers = {Kamondi, Anita/0000-0001-9860-730X} } @article{MTMT:33226625, title = {The sleep EEG envelope is a novel, neuronal firing-based human biomarker}, url = {https://m2.mtmt.hu/api/publication/33226625}, author = {Ujma, Przemyslaw Péter and Dresler, Martin and Simor, Péter Dániel and Fabó, Dániel and Ulbert, István and Erőss, Loránd and Bódizs, Róbert}, doi = {10.1038/s41598-022-22255-4}, journal-iso = {SCI REP}, journal = {SCIENTIFIC REPORTS}, volume = {12}, unique-id = {33226625}, issn = {2045-2322}, abstract = {Sleep EEG reflects voltage differences relative to a reference, while its spectrum reflects its composition of various frequencies. In contrast, the envelope of the sleep EEG reflects the instantaneous amplitude of oscillations, while its spectrum reflects the rhythmicity of the occurrence of these oscillations. The sleep EEG spectrum is known to relate to demographic, psychological and clinical characteristics, but the envelope spectrum has been rarely studied. In study 1, we demonstrate in human invasive data from cortex-penetrating microelectrodes and subdural grids that the sleep EEG envelope spectrum reflects neuronal firing. In study 2, we demonstrate that the scalp EEG envelope spectrum is stable within individuals. A multivariate learning algorithm could predict age (r = 0.6) and sex (r = 0.5) from the EEG envelope spectrum. With age, oscillations shifted from a 4–5 s rhythm to faster rhythms. Our results demonstrate that the sleep envelope spectrum is a promising biomarker of demographic and disease-related phenotypes.}, year = {2022}, eissn = {2045-2322}, orcid-numbers = {Ujma, Przemyslaw Péter/0000-0002-7981-3009; Simor, Péter Dániel/0000-0003-0695-166X; Fabó, Dániel/0000-0001-5141-5351; Ulbert, István/0000-0001-9941-9159; Erőss, Loránd/0000-0002-5796-5546; Bódizs, Róbert/0000-0001-5341-060X} } @article{MTMT:33118864, title = {Clinical parameters predict the effect of bilateral subthalamic stimulation on dynamic balance parameters during gait in Parkinson's disease}, url = {https://m2.mtmt.hu/api/publication/33118864}, author = {Kelemen, Andrea Judit and Halász, László and Muthuraman, Muthuraman and Erőss, Loránd and Barsi, Péter and Zádori, Dénes and Laczó, Bence and Kis, Dávid and Klivényi, Péter and Fekete, Gábor and Bognár, László and Bereczki, Dániel and Tamás, Gertrúd}, doi = {10.3389/fneur.2022.917187}, journal-iso = {FRONT NEUR}, journal = {FRONTIERS IN NEUROLOGY}, volume = {13}, unique-id = {33118864}, issn = {1664-2295}, abstract = {We investigated the effect of deep brain stimulation on dynamic balance during gait in Parkinson's disease with motion sensor measurements and predicted their values from disease-related factors. We recruited twenty patients with Parkinson's disease treated with bilateral subthalamic stimulation for at least 12 months and 24 healthy controls. Six monitors with three-dimensional gyroscopes and accelerometers were placed on the chest, the lumbar region, the two wrists, and the shins. Patients performed the instrumented Timed Up and Go test in stimulation OFF, stimulation ON, and right- and left-sided stimulation ON conditions. Gait parameters and dynamic balance parameters such as double support, peak turn velocity, and the trunk's range of motion and velocity in three dimensions were analyzed. Age, disease duration, the time elapsed after implantation, the Hoehn-Yahr stage before and after the operation, the levodopa, and stimulation responsiveness were reported. We individually calculated the distance values of stimulation locations from the subthalamic motor center in three dimensions. Sway values of static balance were collected. We compared the gait parameters in the OFF and stimulation ON states and controls. With cluster analysis and a machine-learning-based multiple regression method, we explored the predictive clinical factors for each dynamic balance parameter (with age as a confounder). The arm movements improved the most among gait parameters due to stimulation and the horizontal and sagittal trunk movements. Double support did not change after switching on the stimulation on the group level and did not differ from control values. Individual changes in double support and horizontal range of trunk motion due to stimulation could be predicted from the most disease-related factors and the severity of the disease; the latter also from the stimulation-related changes in the static balance parameters. Physiotherapy should focus on double support and horizontal trunk movements when treating patients with subthalamic deep brain stimulation.}, year = {2022}, eissn = {1664-2295}, orcid-numbers = {Kelemen, Andrea Judit/0000-0002-7969-9197; Erőss, Loránd/0000-0002-5796-5546; Barsi, Péter/0000-0002-3574-9973; Zádori, Dénes/0000-0003-0749-7980; Klivényi, Péter/0000-0002-5389-3266; Bereczki, Dániel/0000-0002-8374-0500; Tamás, Gertrúd/0000-0001-8054-3678} } @article{MTMT:33082116, title = {SLEEP MEDICINE: PRACTICE, CHALLENGES AND NEW FRONTIERS}, url = {https://m2.mtmt.hu/api/publication/33082116}, author = {Parrino, Liborio and Halász, Péter and Szűcs, Anna and J Thomas, Robert and Azzi, Nicoletta and Rausa, Francesco and Pizzarotti, Silvia and Zilioli, Alessandro and Misirocchi, Francesco and Mutti, Carlotta}, doi = {10.3389/fneur.2022.966659}, journal-iso = {FRONT NEUR}, journal = {FRONTIERS IN NEUROLOGY}, volume = {13}, unique-id = {33082116}, issn = {1664-2295}, year = {2022}, eissn = {1664-2295}, orcid-numbers = {Szűcs, Anna/0000-0002-9990-5787} } @article{MTMT:33081865, title = {Aspirin mediates its antitumoral effect through inhibiting PTTG1 in pituitary adenoma}, url = {https://m2.mtmt.hu/api/publication/33081865}, author = {Szabó, Borbála and Németh, Kinga and Mészáros, Katalin and Krokker, Lilla and Likó, István and Saskői, Éva and Németh, Krisztina and Szabó, Pál Tamás and Szücs, Nikolette and Czirják, Sándor and Szalóki, Gábor and Patócs, Attila Balázs and Butz, Henriett}, doi = {10.1210/clinem/dgac496}, journal-iso = {J CLIN ENDOCR METAB}, journal = {JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM}, volume = {107}, unique-id = {33081865}, issn = {0021-972X}, abstract = {DNA demethylation and inhibitory effect of Aspirin on pituitary cell proliferation have been demonstrated.was to clarify the molecular mechanisms behind the Aspirin-related effects in pituitary cells.DNA methylome and whole transcriptome profile were investigated in RC4-B/C and GH3 pituitary cell lines upon Aspirin treatment. Effects of Aspirin and demethylation agent, decitabine, were further tested in vitro. PTTG1 expression in 41 human PitNET samples and whole genome gene and protein expression data of 76 PitNET and 34 control samples (available in Gene Expression Omnibus) were evaluated.Aspirin induced global DNA demethylation and consequential transcriptome changes. Overexpression of Tet enzymes and their cofactor Uhrf2 were identified behind the increase of 5-hydroxymethylcytosine (5hmC). Besides cell cycle, proliferation and migration that were validated by functional experiments, Aspirin increased Tp53 activity through p53 acetylation and decreased E2f1 activity. Among the p53 controlled genes, Pttg1 and its interacting partners were downregulated upon Aspirin treatment by inhibiting Pttg1 promoter activity. 5hmC positively correlated with Tet1-3, Tp53 expression, and negatively correlated with Pttg1 expression that was reinforced by the effect of decitabine. Additionally, high overlap (20.15%) was found between Aspirin regulated genes and dysregulated genes in PitNET tissue samples.A novel regulatory network has been revealed, where Aspirin regulated global demethylation, Tp53 activity and Pttg1 expression along with decreased cell proliferation and migration. 5hmC, a novel tissue biomarker in PitNET, indicated Aspirin antitumoral effect in vitro too. Our findings suggest the potential beneficial effect of Aspirin in PitNET.}, keywords = {PITUITARY; METHYLATION; biomarker; demethylation; epigenetic; pituitary adenoma; PTTG1; PitNet}, year = {2022}, eissn = {1945-7197}, pages = {3066-3079}, orcid-numbers = {Németh, Kinga/0000-0002-5009-6149; Likó, István/0000-0001-7668-4726; Saskői, Éva/0000-0001-6691-8576; Szabó, Pál Tamás/0000-0003-2260-4641; Szücs, Nikolette/0000-0002-6614-1311; Czirják, Sándor/0000-0002-8224-3561; Patócs, Attila Balázs/0000-0001-7506-674X; Butz, Henriett/0000-0003-1664-409X} }